Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsSeth Lerner, MD
Assistant Clinical ProfessorAbout
Research
Publications
2026
Early Efficacy and Exploratory Biomarker Data of Bel-sar in Patients with Intermediate-risk and High-risk Non–muscle-invasive Bladder Cancer
Linehan J, Agarwal P, Penny X, Kates M, Jacob J, Lerner S, Kines R, Schiller J, de los Pinos E, Shore N, Hopkins J, McQuaid J, Brookman-May S. Early Efficacy and Exploratory Biomarker Data of Bel-sar in Patients with Intermediate-risk and High-risk Non–muscle-invasive Bladder Cancer. European Urology Open Science 2026, 89: 77-88. PMID: 42325814, PMCID: PMC13279200, DOI: 10.1016/j.euros.2026.05.017.Peer-Reviewed Original ResearchNarrative Review of Potential Non-Surgical Treatments for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Kim S, Gudlavalleti H, Lerner S. Narrative Review of Potential Non-Surgical Treatments for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer. Journal Of Clinical Medicine 2026, 15: 3830. PMID: 42194790, PMCID: PMC13208041, DOI: 10.3390/jcm15103830.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCigarette smoke induces FASN-dependent fatty acid metabolic rewiring to drive bladder cancer progression
Amara C, Piyarathna D, Kamal A, San Chan Y, Reddy K, Ambati C, Hassan M, Shriwas P, Gandhi T, Jain A, Gangnus T, Popli P, Borkar R, Kang S, Summers S, Putluri V, Grimm S, Venkatesh S, Song N, Seeley E, Hedlich-Dwyer J, Chen S, Mahajan N, Jain A, Dobrolecki L, Wells G, Villanueva H, Li J, Liu X, Bollag R, Malovannaya A, Jung S, Lee H, Asangani I, Terris M, Creighton C, Ballester L, Karanam B, Liu S, Lee M, Raju R, Siddiqui M, Eberlin L, Kommagani R, Sreekumar A, Gao J, Young N, Hodges H, Coarfa C, Gassman N, Lerner S, Lotan Y, Putluri N. Cigarette smoke induces FASN-dependent fatty acid metabolic rewiring to drive bladder cancer progression. Cancer Letters 2026, 653: 218562. PMID: 42092682, PMCID: PMC13241086, DOI: 10.1016/j.canlet.2026.218562.Peer-Reviewed Original ResearchLeveraging untargeted metabolomics in combination with machine learning to uncover novel insights into bladder cancer
Kamal A, Putluri V, Gandhi T, Ambati C, Amara C, Kami Reddy K, Spradlin M, Koirala A, Jorvekar S, Grimm S, Fu D, Parsawar K, Jong F, Beecher C, Sen S, Lerner S, Siddiqui M, Lotan Y, Eberlin L, Sreekumar A, Coarfa C, Putluri N. Leveraging untargeted metabolomics in combination with machine learning to uncover novel insights into bladder cancer. Cancer & Metabolism 2026, 14: 8. PMID: 41923172, PMCID: PMC13040883, DOI: 10.1186/s40170-026-00427-4.Peer-Reviewed Original ResearchRadiogenomic analysis of muscle-invasive bladder cancer using CT-based texture analysis
Boyne A, Anderson R, Liu D, Varghese B, Lei X, Hwang D, King K, Dani K, Cen S, Duddalwar V, Lerner S. Radiogenomic analysis of muscle-invasive bladder cancer using CT-based texture analysis. Bladder Cancer 2026, 12: 23523735261455396. PMID: 42221944, PMCID: PMC13219846, DOI: 10.1177/23523735261455396.Peer-Reviewed Original ResearchEnfortumab Vedotin plus Pembrolizumab as Perioperative Therapy
Singh P, Lerner S. Enfortumab Vedotin plus Pembrolizumab as Perioperative Therapy. The New England Journal Of Medicine 2026, 394: 1334-1336. PMID: 41707168, DOI: 10.1056/nejme2515777.Commentaries, Editorials and LettersInterdisciplinary Swiss consensus recommendations for follow-up after radical cystectomy and trimodal treatment for muscle-invasive bladder cancer
Kaufmann E, Aeppli S, Affentranger A, Arnold N, Arnold W, Aschwanden F, Balermpas P, Beyer J, Bieri U, Boormanns J, Cathomas R, De Bari B, Dressler M, Engeler D, Erdmann A, Gallina A, Gomez S, Guckenberger M, Herrmann T, Hermanns T, Lucca I, John H, Kessler T, Klein J, Laouiti M, Lauffer D, Lerner S, Mattei A, Müntener M, Nguyen D, Niederberger P, Papachristofilou A, Prause L, Putora P, Reinhardt K, Salati E, Sèbe P, Shelan M, Sigg S, Strebel R, Templeton A, Vogl U, Wettstein M, Wyler S, Zihler D, Zilli T, Zwahlen D, Roth B, Fankhauser C. Interdisciplinary Swiss consensus recommendations for follow-up after radical cystectomy and trimodal treatment for muscle-invasive bladder cancer. Bladder Cancer 2026, 12: 23523735251410823. PMID: 41550985, PMCID: PMC12811584, DOI: 10.1177/23523735251410823.Peer-Reviewed Original ResearchAlopecia following single-dose postoperative intravesical gemcitabine in nonmuscle-invasive bladder cancer: A multi-institutional case series
Dadabhoy A, Doshi C, Zahir M, Ladi-Seyedian S, Escobar D, Xia L, Schuckman A, Anderson C, Kates M, Agarwal P, Lerner S, Chamie K, Weizer A, Daneshmand S. Alopecia following single-dose postoperative intravesical gemcitabine in nonmuscle-invasive bladder cancer: A multi-institutional case series. Urologic Oncology Seminars And Original Investigations 2026, 44: 110984. PMID: 41529351, DOI: 10.1016/j.urolonc.2025.12.020.Peer-Reviewed Original Research
2025
Clinical Trial in Progress: SWOG S2210, a Phase 2 Study of Neoadjuvant Carboplatin for Localized High-risk Prostate Cancer with Germline BRCA1/2 Mutations
Cheng H, Callis S, Yu E, Delacroix S, Sokolova A, Tangen C, Lerner S, Dorff T, Lin D. Clinical Trial in Progress: SWOG S2210, a Phase 2 Study of Neoadjuvant Carboplatin for Localized High-risk Prostate Cancer with Germline BRCA1/2 Mutations. European Urology Focus 2025, 12: 16-18. PMID: 41354605, PMCID: PMC13242709, DOI: 10.1016/j.euf.2025.11.011.Peer-Reviewed Original ResearchSystemic Therapy for Muscle-Invasive Urothelial Carcinoma of the Bladder (Muscle-Invasive Bladder Cancer): Insights From Real-World Data.
Sadeghi S, Lara P, Necchi A, Gill P, Flaig T, Lerner S, Aron M, Daneshmand S. Systemic Therapy for Muscle-Invasive Urothelial Carcinoma of the Bladder (Muscle-Invasive Bladder Cancer): Insights From Real-World Data. JCO Oncology Practice 2025, op2500464. PMID: 41252668, DOI: 10.1200/op-25-00464.Peer-Reviewed Original Research